myriceron caffeoyl ester: structure given in first source; a novel non-peptide endothelin antagonist isolated from bayberry, Myrica cerifera [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| Flora | Rank | Flora Definition | Family | Family Definition |
|---|---|---|---|---|
| Myrica | genus | A plant genus of the family MYRICACEAE. Members contain myricanol. The common name of bayberry is similar to the name barberry which is used for BERBERIS and MAHONIA.[MeSH] | Myricaceae | A plant family of the order Myricales, subclass Hamamelidae, class Magnoliopsida. They are trees and shrubs having aromatic leaves that often have yellow glandular dots on the surface. Single-seeded fruits are often covered with waxy granules, bumps, or layers. The flowers are small, greenish, and inconspicuous.[MeSH] |
| Myrica cerifera | species | [no description available] | Myricaceae | A plant family of the order Myricales, subclass Hamamelidae, class Magnoliopsida. They are trees and shrubs having aromatic leaves that often have yellow glandular dots on the surface. Single-seeded fruits are often covered with waxy granules, bumps, or layers. The flowers are small, greenish, and inconspicuous.[MeSH] |
| ID Source | ID |
|---|---|
| PubMed CID | 6450144 |
| CHEMBL ID | 3601500 |
| MeSH ID | M0203980 |
| Synonym |
|---|
| olean-12-en-28-oic acid, 27((3-(3,4-dihydroxyphenyl)-1-oxo-2-propenyl)oxy)-3-oxo- |
| 27((3-(3,4-dihydroxyphenyl)-1-oxo-2-propenyl)oxy)-3-oxoolean-12-en-28-oic acid |
| 142877-49-4 |
| myriceron caffeoyl ester |
| chembl3601500 , |
| bdbm50108104 |
| (4as,6ar,6ar,6br,8ar,12ar,14bs)-6a-[[(e)-3-(3,4-dihydroxyphenyl)prop-2-enoyl]oxymethyl]-2,2,6b,9,9,12a-hexamethyl-10-oxo-3,4,5,6,6a,7,8,8a,11,12,13,14b-dodecahydro-1h-picene-4a-carboxylic acid |
| Excerpt | Relevance | Reference |
|---|---|---|
| " Increasing concentrations of 50-235 produced progressive rightwards displacements of the endothelin-1 dose-response curve in each of the three types of blood vessel." | ( Myricerone caffeoyl ester (50-235) is a non-peptide antagonist selective for human ETA receptors. Bacon, CR; Davenport, AP; Fujimoto, M; Maguire, JJ, 1994) | 0.29 |
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Endothelin-1 receptor | Rattus norvegicus (Norway rat) | IC50 (µMol) | 0.0110 | 0.0000 | 1.7746 | 10.0000 | AID1238793 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1238794 | Antagonist activity at endothelin A receptor in Wistar rat thoracic aorta strips assessed as inhibition of ET1-induced vasoconstriction preincubated for 5 mins followed by ET1 addition | 2015 | Bioorganic & medicinal chemistry, Sep-01, Volume: 23, Issue:17 | Chemical synthesis of tetracyclic terpenes and evaluation of antagonistic activity on endothelin-A receptors and voltage-gated calcium channels. |
| AID1238786 | Antagonist activity at endothelin A receptor in Mongolian gerbil spiral modiolar artery assessed as inhibition of ET-1-induced vasoconstriction at 0.1 to 1 uM treated for 2 mins with ET-1 addition for first min of compound treatment followed by compound w | 2015 | Bioorganic & medicinal chemistry, Sep-01, Volume: 23, Issue:17 | Chemical synthesis of tetracyclic terpenes and evaluation of antagonistic activity on endothelin-A receptors and voltage-gated calcium channels. |
| AID1238793 | Antagonist activity at endothelin A receptor in rat A7r5 cells assessed as inhibition of ET-1-induced increase in cytosolic free Ca2+ level treated 1 min prior to ET-1 addition by fura-2 dye-based spectrofluorometric analysis | 2015 | Bioorganic & medicinal chemistry, Sep-01, Volume: 23, Issue:17 | Chemical synthesis of tetracyclic terpenes and evaluation of antagonistic activity on endothelin-A receptors and voltage-gated calcium channels. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 5 (83.33) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (16.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.38) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 6 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||